Literature DB >> 20307191

Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

Stuart H Cohen1, Dale N Gerding, Stuart Johnson, Ciaran P Kelly, Vivian G Loo, L Clifford McDonald, Jacques Pepin, Mark H Wilcox.   

Abstract

Since publication of the Society for Healthcare Epidemiology of America position paper on Clostridium difficile infection in 1995, significant changes have occurred in the epidemiology and treatment of this infection. C. difficile remains the most important cause of healthcare-associated diarrhea and is increasingly important as a community pathogen. A more virulent strain of C. difficile has been identified and has been responsible for more-severe cases of disease worldwide. Data reporting the decreased effectiveness of metronidazole in the treatment of severe disease have been published. Despite the increasing quantity of data available, areas of controversy still exist. This guideline updates recommendations regarding epidemiology, diagnosis, treatment, and infection control and environmental management.

Entities:  

Mesh:

Year:  2010        PMID: 20307191     DOI: 10.1086/651706

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  914 in total

1.  Clostridium difficile prevalence rates in a large healthcare system stratified according to patient population, age, gender, and specimen consistency.

Authors:  J H Boone; M Goodykoontz; S J Rhodes; K Price; J Smith; K N Gearhart; R J Carman; T M Kerkering; T D Wilkins; D M Lyerly
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-14       Impact factor: 3.267

2.  Comparison of GenomEra C. difficile and Xpert C. difficile as confirmatory tests in a multistep algorithm for diagnosis of Clostridium difficile infection.

Authors:  Luis Alcalá; Elena Reigadas; Mercedes Marín; Antonia Fernández-Chico; Pilar Catalán; Emilio Bouza
Journal:  J Clin Microbiol       Date:  2014-11-12       Impact factor: 5.948

Review 3.  Clostridium difficile in the ICU: the struggle continues.

Authors:  Linda D Bobo; Erik R Dubberke; Marin Kollef
Journal:  Chest       Date:  2011-12       Impact factor: 9.410

4.  Fidaxomicin: in Clostridium difficile infection.

Authors:  Sean T Duggan
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

5.  Toxin positivity and tcdB gene load in broad-spectrum Clostridium difficile infection.

Authors:  Hyeong Nyeon Kim; Hanah Kim; Hee-Won Moon; Mina Hur; Yeo-Min Yun
Journal:  Infection       Date:  2017-12-07       Impact factor: 3.553

Review 6.  Clostridium difficile infection: management strategies for a difficult disease.

Authors:  Sahil Khanna; Darrell S Pardi
Journal:  Therap Adv Gastroenterol       Date:  2014-03       Impact factor: 4.409

Review 7.  Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance.

Authors:  Kathleen Mullane
Journal:  Ther Adv Chronic Dis       Date:  2014-03       Impact factor: 5.091

Review 8.  Bezlotoxumab: A Review in Preventing Clostridium difficile Infection Recurrence.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2017-10       Impact factor: 9.546

Review 9.  Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment.

Authors:  Orna Nitzan; Mazen Elias; Bibiana Chazan; Raul Raz; Walid Saliba
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

10.  Role of Coinfecting Strains in Recurrent Clostridium difficile Infection.

Authors:  Janet Sun; Tracy Mc Millen; N Esther Babady; Mini Kamboj
Journal:  Infect Control Hosp Epidemiol       Date:  2016-08-30       Impact factor: 3.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.